248 related articles for article (PubMed ID: 21789746)
1. Attention deficit hyperactivity disorder and substance use disorders.
Bukstein OG
Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
[TBL] [Abstract][Full Text] [Related]
2. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.
Faraone SV; Biederman J; Wilens TE; Adamson J
Psychol Med; 2007 Dec; 37(12):1743-52. PubMed ID: 17349106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
Biederman J
J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
[TBL] [Abstract][Full Text] [Related]
4. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
Faraone SV; Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
[TBL] [Abstract][Full Text] [Related]
5. Does stimulant treatment lead to substance use disorders?
Faraone SV; Wilens T
J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
[TBL] [Abstract][Full Text] [Related]
6. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
[TBL] [Abstract][Full Text] [Related]
7. Attention deficit hyperactivity disorder and substance use disorders.
Szobot CM; Bukstein O
Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
[TBL] [Abstract][Full Text] [Related]
8. What exactly are the benefits of stimulants for ADHD?
Advokat C
J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
[No Abstract] [Full Text] [Related]
9. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders.
Bukstein OG
Expert Rev Neurother; 2006 Apr; 6(4):541-9. PubMed ID: 16623653
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit/hyperactivity disorder and early-onset substance use disorders.
Wilson JJ; Levin FR
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):751-63. PubMed ID: 16262592
[TBL] [Abstract][Full Text] [Related]
11. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use.
Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():4-8. PubMed ID: 18307375
[TBL] [Abstract][Full Text] [Related]
12. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
13. Childhood stimulant treatment and risk for later substance abuse.
Fischer M; Barkley RA
J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
[TBL] [Abstract][Full Text] [Related]
14. ADHD treatment and the risk of substance abuse.
Sircy RA; Stojanoski A
Nurse Pract; 2008 Apr; 33(4):33-6. PubMed ID: 18388552
[No Abstract] [Full Text] [Related]
15. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
Merkel RL; Kuchibhatla A
Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
[TBL] [Abstract][Full Text] [Related]
16. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
Kollins SH
Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605
[TBL] [Abstract][Full Text] [Related]
17. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
Kollins SH
J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit/hyperactivity disorder and substance abuse.
Harstad E; Levy S;
Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
[TBL] [Abstract][Full Text] [Related]
19. Dopamine and serotonin genetic risk scores predicting substance and nicotine use in attention deficit/hyperactivity disorder.
Groenman AP; Greven CU; van Donkelaar MM; Schellekens A; van Hulzen KJ; Rommelse N; Hartman CA; Hoekstra PJ; Luman M; Franke B; Faraone SV; Oosterlaan J; Buitelaar JK
Addict Biol; 2016 Jul; 21(4):915-23. PubMed ID: 25752199
[TBL] [Abstract][Full Text] [Related]
20. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment.
Wilson JJ
Am J Addict; 2007; 16 Suppl 1():5-11; quiz 12-3. PubMed ID: 17453602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
